Exemplos de uso de Tumour response em Inglês e suas traduções para o Português
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
Time to tumour response months.
The primary endpoint was best tumour response.
Best tumour response independent review.
Estimates were calculated by hazard ratios 2 Last tumour response as assessed by the investigator.
Best tumour response in trial STIB2222 GIST.
However, in several studies, the objective criteria for evaluating tumour response are missing or not reported.
Best tumour response investigator assessment.
No clear cutoff for PD-L1 expression can reliably be established when considering the relevant endpoints of tumour response and PFS.
Time to Tumour Response[median(range)] weeks.
Treatment should be maintained in the case of stable disease, i.e. static,partial or complete tumour response, provided that the product is sufficiently well tolerated.
Table 6 Best tumour response in trial STIB2222 GIST.
The evaluations of PFS and ORR were based on blinded independent radiologic assessment of tumour response using the International Workshop Criteria.
Tumour response was assessed at 12-week intervals.
Ten patients achieved a tumour response due to re-treatment.
Last tumour response as assessed by the investigator.
In the 16 patients with MCD treated with 11 mg/kg every 3 weeks,overall tumour response rate by independent review was 43.8% with 6.3% complete response. .
Assessments of tumour response should be conducted only after completion of induction therapy.
In the everolimus treated population(N=111) of the study,including patients who crossed over from the placebo group, tumour response, starting as early as after 12 weeks on everolimus, was sustained at later time points.
Tumour response according to modified-RECIST criteria was determined by central review.
The primary efficacy outcome measure,based on investigator assessed tumour response, was progression-free survival(PFS) of the lenvatinib plus everolimus arm vs the everolimus arm and of the lenvatinib arm vs the everolimus arm.
Tumour response was independent of Odomzo dose or plasma concentration in the dose range of 200 mg to 800 mg.
The objective response rates measured in these subgroups were generally consistent with the PFS results, with the RET mutation positive, negative, andunknown subgroups showing tumour response rates of 32%, 22%, and 25%, respectively.
Assessment of tumour response was conducted every 4 weeks.
Attainment of prostate specific antigen(PSA)reduction Tumour size was not measured directly during the clinical trial programme, but there was an indirect beneficial tumour response as shown by a 95% reduction after 12 months in median PSA for degarelix.
Assessment of tumour response to ipilimumab was conducted at approximately Week 12, after completion of induction therapy.
In a clinical trial of 147 patients with advanced head and neck squamous cell carcinoma, tumour response, defined as a reduction of a minimum of 50% of the tumour mass for a minimum of four weeks, was observed in 25% after a single treatment.
Tumour response was assessed according to the revised International Working Group(IWG) for non-Hodgkin's lymphoma(NHL) criteria.
The proportion of patients with a tumour response(CR, CRu, PR) was significantly higher(p< 0.0001 Chi-Square test) in the R-CVP group(80.9%) than the CVP group 57.2.
Tumour response was assessed by a blinded independent central review panel according to the international workshop to standardise response criteria for NHL.
There was a significant higher rate of tumour response of 14.4%(95%CI: 9.6-19.3) in patients in the JEVTANA arm compared to 4.4%(95%CI: 1.6-7.2) for patients in the mitoxantrone arm, p=0.0005.